Parliamentary Search

Written question asked by John P Smith (Labour) on Thursday, 11 March 2010, in the House of Commons. It was due for an answer on Monday, 15 March 2010. It was answered by Ann Keen (Labour) on Monday, 22 March 2010 on behalf of the Department of Health.

Thromboembolism: Health Services

Question
To ask the Secretary of State for Health (1) how much funding has been allocated to the National Venous Thromboembolism (VTE) Strategy in each of the last five years, excluding funding allocated to the National VTE Commissioning for Quality and Innovation goal;
Answer

The amounts of funding for the areas requested are as follows.The following table represents funding from the Department and its arm's length bodies on the Healthcare Acquired Infection Reduction Strategy. Other organisations have had a role in tackling HCAIs but their expenditure could not be separately identified. For a more detailed breakdown of these costs, please see sections 15 and 16 (p.31-36) of the National Audit Office Report, which can be found at:"www.nao.org.uk/publications/0809/reducing_healthcare_ associated.aspx"

£ million
2004-05 6.5
2005-06 7
2006-07 8
2007-08 10
2008-09 24.5
Total 57
Source: National Audit Office (NAO) report: Reducing Healthcare Associated Infections in Hospitals in England—12 June 2009.

The following table shows funding for venous thromboembolism (VTE) prevention strategy for the past five years and the current financial year. These figures do not include any of the funding related to the national VTE Commissioning for Quality and Innovation (CQUIN) goal. Prior to 2007 the funding of VTE prevention work was limited to expenses for the VTE Expert Working Group members and other related domestic costs for hosting meetings.

£
2004-05 n/a
2005-06 n/a
2006-07 n/a
2007-08 93,500
2008-09 125,936
2009-10 192,764
Total 412,200

A national vaccination programme against human papillomavirus, which causes cervical cancer, began in September 2008. The Department has allocated funds to PCTs for the implementation of the programme. The funding levels (which do not include the cost of the vaccines as this is commercially confidential), which varied by year depending on the number of catch-up cohorts that the vaccine was offered to, were as follows:

£ million
2004-05 n/a
2005-06 n/a
2006-07 n/a
2007-08 n/a
2008-09 18.9
Total 18.9
Current and future funding (£ million)
2009-10 42
2010-11 9.2
Total 52.1

Secondary information

Type
Written question
Reference
508 c129-30W; 322534
Session
2009-10
Subjects
Health services Thromboembolism
Contains statistics
Yes
Link
View this Written question on www.publications.parliament.uk